Crown Laboratories, Inc. has acquired North American distribution rights of five OTC consumer brands from GlaxoSmithKline (GSK). The acquired portfolio includes: PanOxyl® daily acne wash, Sarna® anti-itch lotion, Zeasorb® anti-fungal and prevention product, Desenex® anti-fungal powder for athlete’s foot, and Mineral Ice® pain-relieving gel.
The brands all have a strong heritage and lengthy history in the market. PanOxyl, Sarna, and Zeasorb are three former Stiefel Laboratories brands that have earned #1 Dermatologist Recommended status through decades of strong support from dermatologists.
“Acquiring these strong heritage brands strengthens Crown’s OTC portfolio and adds significant value across multiple categories,” says Jeff Bedard, Crown Laboratories President and CEO. “I am especially excited to bring the Stiefel brands to Crown as I personally enjoyed tremendous success in marketing them as a field sales representative for Stiefel in the 80s and 90s.”
Crown Laboratories has chosen the Emerson Group to manage the sales activity and all logistics for the PanOxyl, Sarna, Zeasorb, Desenex, and Mineral Ice brands across all retailers.
Financial terms of the transaction were not disclosed.